PowerShow.com
  • Help
  • Preferences
  • Sign up
  • Log in
Advanced
Free template

Nnrti PowerPoint PPT Presentations

Grid List
All Time
All TimeAdded TodayAdded This WeekAdded This Month
Show:
Recommended
RecommendedRelevanceLatestHighest RatedMost Viewed
Sort by:
Featured Presentations
Search Results
Statin Interactions with NNRTIs and PIs PowerPoint PPT Presentation
Statin Interactions with NNRTIs and PIs - Statin Interactions with NNRTIs and PIs. Joanne J. Orrick, PharmD, AAHIVE ... Workshop on Clinical Pharmacology of HIV Therapy, Rome, April 2004, abstract 5.2. ...
Statin Interactions with NNRTIs and PIs. Joanne J. Orrick, PharmD, AAHIVE ... Workshop on Clinical Pharmacology of HIV Therapy, Rome, April 2004, abstract 5.2. ...
| PowerPoint PPT presentation | free to view
A longitudinal analysis of liver fibrosis progression among NNRTI and PI users in the Canadian co-infection cohort study PowerPoint PPT Presentation
A longitudinal analysis of liver fibrosis progression among NNRTI and PI users in the Canadian co-infection cohort study - A longitudinal analysis of liver fibrosis progression among NNRTI and PI users in the Canadian co-infection cohort study Laurence Brunet, Erica E. M. Moodie, Jim ...
A longitudinal analysis of liver fibrosis progression among NNRTI and PI users in the Canadian co-infection cohort study Laurence Brunet, Erica E. M. Moodie, Jim ...
| PowerPoint PPT presentation | free to view
TMC278 rilpivirine, an investigational nextgeneration NNRTI, demonstrates longterm efficacy and tole PowerPoint PPT Presentation
TMC278 rilpivirine, an investigational nextgeneration NNRTI, demonstrates longterm efficacy and tole - TMC278 (rilpivirine), an investigational next-generation NNRTI, demonstrates ... (non-completer status equals failure imputation algorithm) ...
TMC278 (rilpivirine), an investigational next-generation NNRTI, demonstrates ... (non-completer status equals failure imputation algorithm) ...
| PowerPoint PPT presentation | free to view
Combined PI and NNRTI Resistance Analysis of the Pooled DUET Trial: Towards a Regimen-Based Resistance Interpretation PowerPoint PPT Presentation
Combined PI and NNRTI Resistance Analysis of the Pooled DUET Trial: Towards a Regimen-Based Resistance Interpretation - Towards a Regimen-Based Resistance Interpretation ... 1Vingerhoets J, et al. Antivir Ther. 2007;12:S34. 2De Meyer S, et al. EHDRW 2008. Abstract 54 ...
Towards a Regimen-Based Resistance Interpretation ... 1Vingerhoets J, et al. Antivir Ther. 2007;12:S34. 2De Meyer S, et al. EHDRW 2008. Abstract 54 ...
| PowerPoint PPT presentation | free to view
A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection  PowerPoint PPT Presentation
A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection - A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing ... Time from randomization to virologic failure (VF) ...
A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing ... Time from randomization to virologic failure (VF) ...
| PowerPoint PPT presentation | free to download
Rapid flux in NNRTI resistance mutations detected in subtype C HIV1 infected women receiving single PowerPoint PPT Presentation
Rapid flux in NNRTI resistance mutations detected in subtype C HIV1 infected women receiving single - 1Division of Infectious Diseases and AIDS research, Stanford University, ... Median Sequential Viral Load Levels in 33 Zimbabwean Women Receiving Single Dose ...
1Division of Infectious Diseases and AIDS research, Stanford University, ... Median Sequential Viral Load Levels in 33 Zimbabwean Women Receiving Single Dose ...
| PowerPoint PPT presentation | free to view
Paradoxical Reaction in TB PowerPoint PPT Presentation
Paradoxical Reaction in TB - HAART involved the use of two NRTIs with either a protease inhibitor (PI) or a non-nucleoside reverse-transcriptase inhibitor (NNRTI). Statistical analysis was ...
HAART involved the use of two NRTIs with either a protease inhibitor (PI) or a non-nucleoside reverse-transcriptase inhibitor (NNRTI). Statistical analysis was ...
| PowerPoint PPT presentation | free to download
Presentaci PowerPoint PPT Presentation
Presentaci - ... Toxic HAART (cART) New families (PI, NNRTI) and cART Big impact on VL, CD4, OI, mortality Metabolic disturbances and lipodystrophy Adherence problems ...
... Toxic HAART (cART) New families (PI, NNRTI) and cART Big impact on VL, CD4, OI, mortality Metabolic disturbances and lipodystrophy Adherence problems ...
| PowerPoint PPT presentation | free to download
When to Start When to Stop What to Start PowerPoint PPT Presentation
When to Start When to Stop What to Start - Boosted PI. NNRTI. NRTI. Unboosted PI. Collated Results of HAART Studies ... Highlights efficacy of boosted-PI and NNRTI regimens. 0. 15. 30. 45. 60. 75. 90 ...
Boosted PI. NNRTI. NRTI. Unboosted PI. Collated Results of HAART Studies ... Highlights efficacy of boosted-PI and NNRTI regimens. 0. 15. 30. 45. 60. 75. 90 ...
| PowerPoint PPT presentation | free to download
New Antiretroviral Agents PowerPoint PPT Presentation
New Antiretroviral Agents - Weill Cornell Medical College. The International AIDS Society USA ... NNRTI: ETR activity depends on NNRTI mutations ( 3 or PT suscept. for optimal activity) ...
Weill Cornell Medical College. The International AIDS Society USA ... NNRTI: ETR activity depends on NNRTI mutations ( 3 or PT suscept. for optimal activity) ...
| PowerPoint PPT presentation | free to view
HIV and AIDS Treatment and Prevention PowerPoint PPT Presentation
HIV and AIDS Treatment and Prevention - HIV and AIDS Treatment and Prevention A focus on Treatment How Drugs Stop HIV/AIDS Where the Drugs Stop HIV Entry or Fusion Inhibitors NRTIs and NNRTIs Integrase ...
HIV and AIDS Treatment and Prevention A focus on Treatment How Drugs Stop HIV/AIDS Where the Drugs Stop HIV Entry or Fusion Inhibitors NRTIs and NNRTIs Integrase ...
| PowerPoint PPT presentation | free to download
Fungal Infections PowerPoint PPT Presentation
Fungal Infections - Dermatophytoses and onychomycosis. DRUG INTERACTIONS Many can occur due to inhibition of CYP 3A4 (e.g. PIs,NNRTIs,anticancer drugs). FLUCONAZOLE (Diflucan) ...
Dermatophytoses and onychomycosis. DRUG INTERACTIONS Many can occur due to inhibition of CYP 3A4 (e.g. PIs,NNRTIs,anticancer drugs). FLUCONAZOLE (Diflucan) ...
| PowerPoint PPT presentation | free to download
Clinical%20Manifestations%20and%20Treatment%20of%20HIV PowerPoint PPT Presentation
Clinical%20Manifestations%20and%20Treatment%20of%20HIV - Contrast scan - multiple enhancing lesions, basal ganglia, gray-white junction ... If an NNRTI-based regimen is used, EFZ would be the preferred drug as its ...
Contrast scan - multiple enhancing lesions, basal ganglia, gray-white junction ... If an NNRTI-based regimen is used, EFZ would be the preferred drug as its ...
| PowerPoint PPT presentation | free to download
Human Immunodeficiency Virus and Antiretroviral Therapy PowerPoint PPT Presentation
Human Immunodeficiency Virus and Antiretroviral Therapy - Human Immunodeficiency Virus and Antiretroviral Therapy. Lucille ... ART Drug Classes and Mechanisms of Action: NNRTIs ... 3. Current ARV mechanisms of action: ...
Human Immunodeficiency Virus and Antiretroviral Therapy. Lucille ... ART Drug Classes and Mechanisms of Action: NNRTIs ... 3. Current ARV mechanisms of action: ...
| PowerPoint PPT presentation | free to view
Characterization of In Vitro Release and In Vivo Delivery of TMC120 with an Intravaginal Ring: Impli PowerPoint PPT Presentation
Characterization of In Vitro Release and In Vivo Delivery of TMC120 with an Intravaginal Ring: Impli - NNRTI developed by Tibotec/J&J, licensed to IPM (2004) ... Low cytotoxicity, non-mutagenic, non-teratogenic. Easily manufactured. Stable drug substance ...
NNRTI developed by Tibotec/J&J, licensed to IPM (2004) ... Low cytotoxicity, non-mutagenic, non-teratogenic. Easily manufactured. Stable drug substance ...
| PowerPoint PPT presentation | free to view
Tolrance des antirtroviraux Gestion des effets secondaires PowerPoint PPT Presentation
Tolrance des antirtroviraux Gestion des effets secondaires - More common with PIs. Include hyperlipidaemia, insulin resistance and ... Skin rashes and hypersensitivity reactions, more common with the NNRTI drugs but also ...
More common with PIs. Include hyperlipidaemia, insulin resistance and ... Skin rashes and hypersensitivity reactions, more common with the NNRTI drugs but also ...
| PowerPoint PPT presentation | free to view
Adherence in the new era of HAART A call for community pharmacists PowerPoint PPT Presentation
Adherence in the new era of HAART A call for community pharmacists - Recognize the relationship between adherence and successful outcomes in the new ... 109 indigent patients in San Francisco. 56 unboosted PI, 53 NNRTI regimen ...
Recognize the relationship between adherence and successful outcomes in the new ... 109 indigent patients in San Francisco. 56 unboosted PI, 53 NNRTI regimen ...
| PowerPoint PPT presentation | free to view
Group%20Work%20Recommendations-what%20to%20start PowerPoint PPT Presentation
Group%20Work%20Recommendations-what%20to%20start - PMTCT exposed : PI or close monitoring of NNRTI. No PMTCT: ... Benefits outweigh risks. Strong. Explanation. Decision. Feasibility. Conditional on availability ...
PMTCT exposed : PI or close monitoring of NNRTI. No PMTCT: ... Benefits outweigh risks. Strong. Explanation. Decision. Feasibility. Conditional on availability ...
| PowerPoint PPT presentation | free to download
Replicative cycle of HIV-1 and Therapy PowerPoint PPT Presentation
Replicative cycle of HIV-1 and Therapy - Polymerase and RNase H active sites of HIV-1 RT. 17-18 bp. p51. p66. p66. p51. DNAn 1. DNAn ... Structures of NON-nucleoside analogue RT inhibitors (NNRTIs) ...
Polymerase and RNase H active sites of HIV-1 RT. 17-18 bp. p51. p66. p66. p51. DNAn 1. DNAn ... Structures of NON-nucleoside analogue RT inhibitors (NNRTIs) ...
| PowerPoint PPT presentation | free to view
Antiretroviral Activity and Tolerability of Reverset Dd4FC, a New FluoroCytidine Nucleoside Analog w PowerPoint PPT Presentation
Antiretroviral Activity and Tolerability of Reverset Dd4FC, a New FluoroCytidine Nucleoside Analog w - Active with viral mutants resistant to 3TC, AZT, TDF, other NRTIs, NNRTIs and PIs ... 2-Week Viral Load Decline With 200 mg RVT ...
Active with viral mutants resistant to 3TC, AZT, TDF, other NRTIs, NNRTIs and PIs ... 2-Week Viral Load Decline With 200 mg RVT ...
| PowerPoint PPT presentation | free to download
Starting children and infants on ART what do the guidelines say PowerPoint PPT Presentation
Starting children and infants on ART what do the guidelines say - Non NNRTI exposure. Unknown infant. maternal MTCT. Exposure. NVP triple ART. PI triple ART ... 2006 guidelines (being updated to reflect above) ...
Non NNRTI exposure. Unknown infant. maternal MTCT. Exposure. NVP triple ART. PI triple ART ... 2006 guidelines (being updated to reflect above) ...
| PowerPoint PPT presentation | free to view
The MONET trial: darunavirritonavir monotherapy shows noninferior efficacy to standard HAART, for pa PowerPoint PPT Presentation
The MONET trial: darunavirritonavir monotherapy shows noninferior efficacy to standard HAART, for pa - The MONET trial: darunavir/ritonavir monotherapy shows non ... MONET - Trial Design. Taking 2 NRTI either NNRTI or boosted PI at ... MONET: Study ...
The MONET trial: darunavir/ritonavir monotherapy shows non ... MONET - Trial Design. Taking 2 NRTI either NNRTI or boosted PI at ... MONET: Study ...
| PowerPoint PPT presentation | free to view
Julio Montaner MD, FRCPC, FCCP PowerPoint PPT Presentation
Julio Montaner MD, FRCPC, FCCP - Director, BC-Centre for Excellence on HIV/AIDS. Professor of Medicine and ... ATV/rtv. fosAMP/rtv. SQV/rtv. NNRTI component. EFV. NVP* In selected patients ...
Director, BC-Centre for Excellence on HIV/AIDS. Professor of Medicine and ... ATV/rtv. fosAMP/rtv. SQV/rtv. NNRTI component. EFV. NVP* In selected patients ...
| PowerPoint PPT presentation | free to view
Go Undetectable Why LowLevel Viremia Is Not an Option PowerPoint PPT Presentation
Go Undetectable Why LowLevel Viremia Is Not an Option - 44% of Patients Developed at Least One New Drug Resistance Mutation Over One Year ... Accumulation of resistance. From 1st-line/2nd-line ... NNRTI 2 NRTI. PI ...
44% of Patients Developed at Least One New Drug Resistance Mutation Over One Year ... Accumulation of resistance. From 1st-line/2nd-line ... NNRTI 2 NRTI. PI ...
| PowerPoint PPT presentation | free to view
Options for Deep Salvage Therapy: Now and in the Future A Clinical Perspective on the Management of PowerPoint PPT Presentation
Options for Deep Salvage Therapy: Now and in the Future A Clinical Perspective on the Management of - Response to NNRTI-HAART in women who received SD-NVP (MTCT) ... higher' - FC at which response is essentially gone (80% in response) Step 4: Validation ...
Response to NNRTI-HAART in women who received SD-NVP (MTCT) ... higher' - FC at which response is essentially gone (80% in response) Step 4: Validation ...
| PowerPoint PPT presentation | free to view
Resistance Interpretation Starting from Basic PowerPoint PPT Presentation
Resistance Interpretation Starting from Basic - This speaker has the following significant financial ... J Virology 2002; 766:1753; 4. Chan K, et al. AIDS 2003; 17:1256. n=101. NNRTI (n=9) NRTI (n=3) ...
This speaker has the following significant financial ... J Virology 2002; 766:1753; 4. Chan K, et al. AIDS 2003; 17:1256. n=101. NNRTI (n=9) NRTI (n=3) ...
| PowerPoint PPT presentation | free to view
Future Applications of Antiretroviral Agents in Development PowerPoint PPT Presentation
Future Applications of Antiretroviral Agents in Development - Novel NNRTI designed to have a high genetic barrier to ... Diarrhea, nausea, fatigue, ISRs, headache, pruritus. Occurring in 5% of 2 patients per arm ...
Novel NNRTI designed to have a high genetic barrier to ... Diarrhea, nausea, fatigue, ISRs, headache, pruritus. Occurring in 5% of 2 patients per arm ...
| PowerPoint PPT presentation | free to view
Draft WHO Pediatric ARV Guidelines Revision Summary PowerPoint PPT Presentation
Draft WHO Pediatric ARV Guidelines Revision Summary - ... with increased monitoring (LFT) who concurrent boosted PI and rifampin rx. Adult group to advocate for availability of rifabutin (then can give boosted PI or NNRTI) ...
... with increased monitoring (LFT) who concurrent boosted PI and rifampin rx. Adult group to advocate for availability of rifabutin (then can give boosted PI or NNRTI) ...
| PowerPoint PPT presentation | free to view
A Multicultural Caribbean United Against HIVAIDS Mother to Infant HIV Transmission: State of the Art PowerPoint PPT Presentation
A Multicultural Caribbean United Against HIVAIDS Mother to Infant HIV Transmission: State of the Art - Taha T. 2002 AIDS Conf, Barcelona Abs ThPpD2146. NB NVP. NB NVP. NB ... Summary: Virologic Response ( 400 & 50) to NNRTI-Based Therapy by Prior History SD NVP ...
Taha T. 2002 AIDS Conf, Barcelona Abs ThPpD2146. NB NVP. NB NVP. NB ... Summary: Virologic Response ( 400 & 50) to NNRTI-Based Therapy by Prior History SD NVP ...
| PowerPoint PPT presentation | free to view
DPC 083 ATAC Meeting Seattle February 24, 2002 PowerPoint PPT Presentation
DPC 083 ATAC Meeting Seattle February 24, 2002 - NNRTI DPC 083 vs 600 mg Efavirenz (EFV) ... A. Rachlis, J.R. Arribas, L.Ploughman, W. Fiske, ... L.T. Bacheler, L. Ploughman, P.Tsang, D.Labriola, R. Echols, ...
NNRTI DPC 083 vs 600 mg Efavirenz (EFV) ... A. Rachlis, J.R. Arribas, L.Ploughman, W. Fiske, ... L.T. Bacheler, L. Ploughman, P.Tsang, D.Labriola, R. Echols, ...
| PowerPoint PPT presentation | free to view
New Antiretroviral Agents PowerPoint PPT Presentation
New Antiretroviral Agents - International AIDS Society USA ... ATV. FTC. FPV. TPV. DRV. ETR. RAL MVC. Slide 3 ... do NOT use with other NNRTI, unboosted PI, ATV/r, FPV/r, TPV/r, RIF, antiseizure ...
International AIDS Society USA ... ATV. FTC. FPV. TPV. DRV. ETR. RAL MVC. Slide 3 ... do NOT use with other NNRTI, unboosted PI, ATV/r, FPV/r, TPV/r, RIF, antiseizure ...
| PowerPoint PPT presentation | free to view
Global Antiretroviral Drugs Market PowerPoint PPT Presentation
Global Antiretroviral Drugs Market - The report analyses the Antiretroviral Market By Drug Type (Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others). The report analyses the antiretroviral market, By Region (North America, Europe, Asia Pacific, Rest of the World) and By Country (U.S., Canada, Germany, U.K, France, Italy, China, Japan, India, and South Africa) for the historical period of 2013-2017 and the forecast period of 2018-2023. This report also includes drug sales forecast for some antiretroviral drugs. Request free Sample of this Report @: http://azothanalytics.com/report/healthcare-pharma/global-antiretroviral-drugs-market-analysis-by-drug-type-multi-class-drugs-combination-drugs-nrti-nnrti-protease-inhibitors-by-region-by-country-drug-forecast-2019-edition-opportunities-and-forecast-2013-2023-r32196
The report analyses the Antiretroviral Market By Drug Type (Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others). The report analyses the antiretroviral market, By Region (North America, Europe, Asia Pacific, Rest of the World) and By Country (U.S., Canada, Germany, U.K, France, Italy, China, Japan, India, and South Africa) for the historical period of 2013-2017 and the forecast period of 2018-2023. This report also includes drug sales forecast for some antiretroviral drugs. Request free Sample of this Report @: http://azothanalytics.com/report/healthcare-pharma/global-antiretroviral-drugs-market-analysis-by-drug-type-multi-class-drugs-combination-drugs-nrti-nnrti-protease-inhibitors-by-region-by-country-drug-forecast-2019-edition-opportunities-and-forecast-2013-2023-r32196
| PowerPoint PPT presentation | free to download
Making antiretroviral therapy forever PowerPoint PPT Presentation
Making antiretroviral therapy forever - ... 5 x ULN women CD4 250 11% CD4 250 1% men CD4 400 6 ... Relative risk 1.17 per year of ART 1.16 per year of PI therapy 0.94 per year of NNRTI therapy ...
... 5 x ULN women CD4 250 11% CD4 250 1% men CD4 400 6 ... Relative risk 1.17 per year of ART 1.16 per year of PI therapy 0.94 per year of NNRTI therapy ...
| PowerPoint PPT presentation | free to view
Style F 24 by 48 PowerPoint PPT Presentation
Style F 24 by 48 - Title: Style F 24 by 48 Author: Steve Berry Last modified by: Steve Created Date: 7/27/2004 6:54:58 PM Document presentation format: Custom Company
Title: Style F 24 by 48 Author: Steve Berry Last modified by: Steve Created Date: 7/27/2004 6:54:58 PM Document presentation format: Custom Company
| PowerPoint PPT presentation | free to download
Influence of Baseline Factors on Virologic Response to Darunavir/Ritonavir (DRV/r) vs Lopinavir/r (LPV/r): Week 48 Outcome in TITAN PowerPoint PPT Presentation
Influence of Baseline Factors on Virologic Response to Darunavir/Ritonavir (DRV/r) vs Lopinavir/r (LPV/r): Week 48 Outcome in TITAN - Influence of Baseline Factors on Virologic Response to Darunavir/Ritonavir (DRV/r) vs Lopinavir/r (LPV/r): Week 48 Outcome in TITAN W. David Hardy, MD1; Daniel Berger ...
Influence of Baseline Factors on Virologic Response to Darunavir/Ritonavir (DRV/r) vs Lopinavir/r (LPV/r): Week 48 Outcome in TITAN W. David Hardy, MD1; Daniel Berger ...
| PowerPoint PPT presentation | free to download
AntiHIV Agents in Clinical Use Act at Critical Stages in the Viral Replication Cycle PowerPoint PPT Presentation
AntiHIV Agents in Clinical Use Act at Critical Stages in the Viral Replication Cycle - Anti-HIV Agents in Clinical Use. Act at Critical Stages in the. Viral Replication Cycle ... Porcine 4-day vaginal irritation study (3/gp): No adverse effects ...
Anti-HIV Agents in Clinical Use. Act at Critical Stages in the. Viral Replication Cycle ... Porcine 4-day vaginal irritation study (3/gp): No adverse effects ...
| PowerPoint PPT presentation | free to view
AntiHIV Agents in Clinical Use Act at Critical Stages in the Viral Replication Cycle PowerPoint PPT Presentation
AntiHIV Agents in Clinical Use Act at Critical Stages in the Viral Replication Cycle - Anti-HIV Agents in Clinical Use. Act at Critical Stages in the. Viral Replication Cycle ... 20% Propylene glycol. 20% PEG 200. Water. Captex 300 ...
Anti-HIV Agents in Clinical Use. Act at Critical Stages in the. Viral Replication Cycle ... 20% Propylene glycol. 20% PEG 200. Water. Captex 300 ...
| PowerPoint PPT presentation | free to view
Persistent immune activation despite suppressive HAART is associated with higher risk for viral blips in HIV-1 infected individuals PowerPoint PPT Presentation
Persistent immune activation despite suppressive HAART is associated with higher risk for viral blips in HIV-1 infected individuals - Persistent immune activation despite suppressive HAART is associated with higher risk for viral blips in HIV-1 infected individuals Alexander Zoufaly1*, Jan G Kiepe1 ...
Persistent immune activation despite suppressive HAART is associated with higher risk for viral blips in HIV-1 infected individuals Alexander Zoufaly1*, Jan G Kiepe1 ...
| PowerPoint PPT presentation | free to download
Guidelines published as an update on 2003 guidelines. About 8-9 pages. New data only PowerPoint PPT Presentation
Guidelines published as an update on 2003 guidelines. About 8-9 pages. New data only - Brian West: BHIVA Guidelines What s new: Guidelines published as an update on 2003 guidelines. About 8-9 pages. New data only Look at new backbones of therapy?
Brian West: BHIVA Guidelines What s new: Guidelines published as an update on 2003 guidelines. About 8-9 pages. New data only Look at new backbones of therapy?
| PowerPoint PPT presentation | free to download
??HIV???????????????? PowerPoint PPT Presentation
??HIV???????????????? - hiv hiv
hiv hiv
| PowerPoint PPT presentation | free to download
Avances en el tratamiento del VIH M PowerPoint PPT Presentation
Avances en el tratamiento del VIH M - Avances en el tratamiento del VIH M . Paloma Geijo Mart nez MI-Infecciosas. Hospital Virgen de la Luz. Cuenca XI Congreso de la Sociedad de Medicina Interna Madrid ...
Avances en el tratamiento del VIH M . Paloma Geijo Mart nez MI-Infecciosas. Hospital Virgen de la Luz. Cuenca XI Congreso de la Sociedad de Medicina Interna Madrid ...
| PowerPoint PPT presentation | free to download
Virology Resistance PowerPoint PPT Presentation
Virology Resistance - Virology - Resistance. Anna Maria Geretti. Royal Free Hospital, London ... Evolution towards high resistance and high fitness. Emergence ...
Virology - Resistance. Anna Maria Geretti. Royal Free Hospital, London ... Evolution towards high resistance and high fitness. Emergence ...
| PowerPoint PPT presentation | free to view
Draft WHO Pediatric ARV Guidelines Revision Summary PowerPoint PPT Presentation
Draft WHO Pediatric ARV Guidelines Revision Summary - Draft WHO Pediatric ARV Guidelines Revision Summary Lynne M. Mofenson, M.D. Pediatric, Adolescent and Maternal AIDS Branch National Institute of Child Health and ...
Draft WHO Pediatric ARV Guidelines Revision Summary Lynne M. Mofenson, M.D. Pediatric, Adolescent and Maternal AIDS Branch National Institute of Child Health and ...
| PowerPoint PPT presentation | free to download
Presentazione di PowerPoint PowerPoint PPT Presentation
Presentazione di PowerPoint - Farmaci anti-retrovirali attualmente (2007) approvati Farmaci anti-retrovirali attualmente (2007) approvati Farmaci anti-retrovirali attualmente (2007) approvati ...
Farmaci anti-retrovirali attualmente (2007) approvati Farmaci anti-retrovirali attualmente (2007) approvati Farmaci anti-retrovirali attualmente (2007) approvati ...
| PowerPoint PPT presentation | free to download
Presentazione di PowerPoint PowerPoint PPT Presentation
Presentazione di PowerPoint - H I V * Mechanism of action of bicyclams: inhibiting viral entry by blocking the CXCR4 receptor. During the viral adsorption process, a | the viral envelope ...
H I V * Mechanism of action of bicyclams: inhibiting viral entry by blocking the CXCR4 receptor. During the viral adsorption process, a | the viral envelope ...
| PowerPoint PPT presentation | free to download
Influence%20of%20Baseline%20Factors%20on%20Virologic%20Response%20to%20Darunavir/Ritonavir%20(DRV/r)%20vs%20Lopinavir/r%20(LPV/r):%20Week%2048%20Outcome%20in%20TITAN PowerPoint PPT Presentation
Influence%20of%20Baseline%20Factors%20on%20Virologic%20Response%20to%20Darunavir/Ritonavir%20(DRV/r)%20vs%20Lopinavir/r%20(LPV/r):%20Week%2048%20Outcome%20in%20TITAN - 1Cedars-Sinai Medical Center, Los Angeles, CA, USA; 2Northstar Medical Center, ... Yardley, PA, USA; and 5Tibotec Therapeutics, Bridgewater, NJ, USA ...
1Cedars-Sinai Medical Center, Los Angeles, CA, USA; 2Northstar Medical Center, ... Yardley, PA, USA; and 5Tibotec Therapeutics, Bridgewater, NJ, USA ...
| PowerPoint PPT presentation | free to download
Antiretroviral Drug Interactions PowerPoint PPT Presentation
Antiretroviral Drug Interactions - This speaker has the following significant financial ... This set has been peer-reviewed to ensure that there are ... Tadalafil (Cialis ): max dose 10 ...
This speaker has the following significant financial ... This set has been peer-reviewed to ensure that there are ... Tadalafil (Cialis ): max dose 10 ...
| PowerPoint PPT presentation | free to view
Guidelines published as an update on 2003 guidelines. About 89 pages. New data only PowerPoint PPT Presentation
Guidelines published as an update on 2003 guidelines. About 89 pages. New data only - ( Importance of resistance testing...) Emphasise that all PIs to be ... 7/8 had VL drop of at least 0.5 log 4 with VL below 400. Next phase sees 180 recruited ...
( Importance of resistance testing...) Emphasise that all PIs to be ... 7/8 had VL drop of at least 0.5 log 4 with VL below 400. Next phase sees 180 recruited ...
| PowerPoint PPT presentation | free to view
ADAP ADVOCACY ASSOCIATION'S 6TH ANNUAL CONFERENCE PowerPoint PPT Presentation
ADAP ADVOCACY ASSOCIATION'S 6TH ANNUAL CONFERENCE - ... PH.D. ROBERTCALDWELL@ICLOUD.COM ADDITIONAL SLIDES www.hcvadvocate.org Zidovudine(Azidothymidine, AZT) AZT was the first approved treatment for HIV, ...
... PH.D. ROBERTCALDWELL@ICLOUD.COM ADDITIONAL SLIDES www.hcvadvocate.org Zidovudine(Azidothymidine, AZT) AZT was the first approved treatment for HIV, ...
| PowerPoint PPT presentation | free to download
Initial Treatment:  Preferred Regimens PowerPoint PPT Presentation
Initial Treatment: Preferred Regimens - PLWHA age 15 to 49 years old in the U.S. eligible for ART in 2003 was 480,000. ... CD4 T cell counts 400 cells/mm3, unless the benefit clearly outweighs the risk. ...
PLWHA age 15 to 49 years old in the U.S. eligible for ART in 2003 was 480,000. ... CD4 T cell counts 400 cells/mm3, unless the benefit clearly outweighs the risk. ...
| PowerPoint PPT presentation | free to view
Hierarchical Database Screenings for HIV-1 Reverse Transcriptase Using a Pharmacophore Model, Rigid Docking, Solvation Docking, and MM-PB/SA PowerPoint PPT Presentation
Hierarchical Database Screenings for HIV-1 Reverse Transcriptase Using a Pharmacophore Model, Rigid Docking, Solvation Docking, and MM-PB/SA - ... (non-nucleoside reverse transcriptase ... Of inhibitor mass center were allowed to move during the simulations Equilibration for 50 ps 20 snapshots ...
... (non-nucleoside reverse transcriptase ... Of inhibitor mass center were allowed to move during the simulations Equilibration for 50 ps 20 snapshots ...
| PowerPoint PPT presentation | free to download
Initial Antiretroviral Therapy and Early Treatment Failure: Case-based Discussion PowerPoint PPT Presentation
Initial Antiretroviral Therapy and Early Treatment Failure: Case-based Discussion - Initial Antiretroviral Therapy and Early Treatment Failure: Casebased Discussion
Initial Antiretroviral Therapy and Early Treatment Failure: Casebased Discussion
| PowerPoint PPT presentation | free to view
Introductory talk PowerPoint PPT Presentation
Introductory talk - INTRODUCTORY TALK D Costagliola Chapter 1 THE CURRENT DEBATE ON ABACAVIR Study Design CV Events Effect of ABC? D:A:D[1] (N of MI = 580) Observational cohort ...
INTRODUCTORY TALK D Costagliola Chapter 1 THE CURRENT DEBATE ON ABACAVIR Study Design CV Events Effect of ABC? D:A:D[1] (N of MI = 580) Observational cohort ...
| PowerPoint PPT presentation | free to download
Disparate Virologic Response to HAART between Ethnicities PowerPoint PPT Presentation
Disparate Virologic Response to HAART between Ethnicities - Disparate Virologic Response to HAART between Ethnicities Amy Weintrob1,2, Greg Grandits2,3, Brian Agan2,4, Anuradha Ganesan2,5, Nancy Crum-Cianflone2,6, Susan ...
Disparate Virologic Response to HAART between Ethnicities Amy Weintrob1,2, Greg Grandits2,3, Brian Agan2,4, Anuradha Ganesan2,5, Nancy Crum-Cianflone2,6, Susan ...
| PowerPoint PPT presentation | free to download
Nuevas tcnicas de deteccin de poblaciones minoritarias en infeccin por VIH: posibles usos y limitaci PowerPoint PPT Presentation
Nuevas tcnicas de deteccin de poblaciones minoritarias en infeccin por VIH: posibles usos y limitaci - ... f fff3f3 33 3f333 f3 f 3 f 3 f 3 f f f ff f3 f 3 ... f f f f ff 3f ff ffff fffff3fff3 f3f3 f3ff33f3f ff fff3f3 3 3 3 f3 ...
... f fff3f3 33 3f333 f3 f 3 f 3 f 3 f f f ff f3 f 3 ... f f f f ff 3f ff ffff fffff3fff3 f3f3 f3ff33f3f ff fff3f3 3 3 3 f3 ...
| PowerPoint PPT presentation | free to view
Objective of the DAP PowerPoint PPT Presentation
Objective of the DAP - Phenotypic Measures of resistance are based upon the fold-resistance ... H Baseline log10 HIV-1 RNA, New Drug Covariates, PSS - 10-fold cutoff (A, B, D) ...
Phenotypic Measures of resistance are based upon the fold-resistance ... H Baseline log10 HIV-1 RNA, New Drug Covariates, PSS - 10-fold cutoff (A, B, D) ...
| PowerPoint PPT presentation | free to download
Page of  


PowerPlugs
PowerPlugs
View by Category
Presentations
  • Photo Slideshows
  • Presentations (free-to-view)
    • Concepts & Trends
    • Entertainment
    • Fashion & Beauty
    • Government & Politics
    • How To, Education & Training
    • Medicine, Science & Technology
    • Other
    • Pets & Animals
    • Products & Services
    • Religious & Philosophical
    • Travel & Places
  • Presentations (pay-to-view)
Products Sold on our sister site CrystalGraphics.com
  • Ultimate Combo for PPT
  • PowerPoint Templates
  • Charts & Diagrams for PPT
  • 3D Character Slides
  • Background Videos for PPT
  • More Products for PPT
PowerPlugs
PowerPlugs
CrystalGraphics
Home About Us Terms and Conditions Privacy Policy Contact Us Send Us Feedback
Copyright 2021 CrystalGraphics, Inc. — All rights Reserved. PowerShow.com is a trademark of CrystalGraphics, Inc.
nnrti — Search results on PowerShow.com
Loading...